[Federal Register Volume 84, Number 156 (Tuesday, August 13, 2019)]
[Notices]
[Pages 40020-40021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17242]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-44-2019]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico; Notification 
of Proposed Production Activity; Patheon Puerto Rico, Inc. 
(Pharmaceutical Products); Manat[iacute], Puerto Rico

    The Puerto Rico Industrial Development Company, grantee of FTZ 7, 
submitted a notification of proposed production activity to the FTZ 
Board on behalf of Patheon Puerto Rico, Inc. (Patheon), located in 
Manat[iacute], Puerto Rico. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on August 2, 2019.
    Patheon already has authority to produce certain pharmaceutical 
products within FTZ 7. The current request would add a finished product 
and foreign status materials/components to the scope of authority. 
Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited 
to the specific foreign-status materials/components and specific 
finished product described in the submitted notification (as described 
below) and subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt Patheon from customs 
duty payments on the foreign-status materials/components used in export 
production. On its domestic sales, for the foreign-status materials/
components noted below and in the existing scope of authority, Patheon 
would be able to choose the duty rates during customs entry procedures 
that apply to empaglifozin and metformin hydrochloride tablets (duty-
free). Patheon would be able to avoid duty on foreign-status components 
which become scrap/waste. Customs duties also could possibly be 
deferred or

[[Page 40021]]

reduced on foreign-status production equipment.
    The materials/components sourced from abroad include: 
Emapaglifozin--active pharmaceutical ingredient; metformin 
hydrochloride; copovidone; silica, colloidal anhydrous; magnesium 
stearate; opadry (coating); and, corn (maize) starch (duty rate ranges 
from duty-free to 6.5%).
    The request indicates that certain materials/components are subject 
to special duties under Section 301 of the Trade Act of 1974 (Section 
301), depending on the country of origin. The applicable Section 301 
decisions require subject merchandise to be admitted to FTZs in 
privileged foreign status (19 CFR 146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is September 23, 
2019.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected] or (202) 482-1963.

    Dated: August 7, 2019.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2019-17242 Filed 8-12-19; 8:45 am]
 BILLING CODE 3510-DS-P